Verseon International Corporation has announced that its noval AI technology, VersAI™, demonstrates superior prediction ...

Pfizer announced that its combination therapy of BRAFTOVI® (encorafenib) and MEKTOVI® (binimetinib) has demonstrated ...

We welcomed two special guests, Dr. Stacy Lindborg, CEO of IMUNON, and Dr. Premal Thaker, Gynecologic Oncologist at Washington University, to discuss the results of the OVATION 2 Study and the latest ...

In this exclusive interview, we welcome Caroline Loew, CEO of Mural Oncology, to discuss the potential of cytokine-based immunotherapies for cancer treatment. Additionally, we will explore the ...

The FDA has approved the Altius® System, an innovative device for managing chronic pain in lower limb amputees. Utilizing direct electrical nerve stimulation, the device proved effective in reducing ...

The next-generation weight loss therapeutic, nimacimab, has entered the Phase 2 CBeyond clinical trial. The study aims to determine the safety of nimacimab, focusing on sustainable weight loss and ...